1.
Clin Immunol
; 222: 108639, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33259966
RESUMO
Complete remission from recurrent EBV-positive lymphoma is not mandatory before HSCT to achieve long-term cure in a patient suffering from a recently described immunodeficiency affecting the T-cell coactivation molecule 4-1BB.